Your session is about to expire
← Back to Search
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos (COMPASS-HCM Trial)
N/A
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Eligible Conditions
- Hypertrophic Cardiomyopathy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2024 Phase 3 trial • 112 Patients • NCT043490729%
Fatigue
8%
Dizziness
7%
Headache
6%
Dyspnoea
6%
Palpitations
6%
Dyspnoea exertional
6%
Hypertension
6%
Arthralgia
3%
Atrial fibrillation
1%
Peripheral venous disease
1%
Cardiac failure congestive
1%
Acute respiratory failure
1%
Gastrooesophageal reflux disease
1%
Sudden cardiac death
1%
Fall
1%
Large intestine perforation
1%
Pneumatosis intestinalis
1%
Nephrolithiasis
1%
Pulmonary embolism
1%
COVID-19
1%
Clostridium difficile infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mavacamten
Placebo
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: MavacamtenExperimental Treatment1 Intervention
Adult participants with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mavacamten
2022
Completed Phase 3
~530
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,098,953 Total Patients Enrolled